Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes

被引：0
|
作者：
Ulf Hannelius
Craig A. Beam
Johnny Ludvigsson
机构：
[1] Diamyd Medical AB,Department of Biomedical Sciences
[2] Western Michigan University Homer Stryker M.D. School of Medicine,Division of Pediatrics, Department of Biomedical and Clinical Sciences (BKV), Medical Faculty
[3] Crown Princess Victoria Children’s Hospital,undefined
[4] Linköping University,undefined
来源：
Diabetologia | 2020年 / 63卷
关键词：
Antigen-specific; Autoimmune diabetes; C-peptide; GAD; Glutamic acid decarboxylase; HLA; Immunotherapy; Type 1 diabetes; Vaccine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2177 / 2181
页数：4
相关论文
共 49 条
  • [1] Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes
    Hannelius, Ulf
    Beam, Craig A.
    Ludvigsson, Johnny
    DIABETOLOGIA, 2020, 63 (10) : 2177 - 2181
  • [2] GAD-alum immunotherapy in Type 1 diabetes mellitus
    Morales, Alba E.
    Thrailkill, Kathryn M.
    IMMUNOTHERAPY, 2011, 3 (03) : 323 - 332
  • [3] Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2
    Nowak, Christoph
    Lind, Marcus
    Sumnik, Zdenek
    Pelikanova, Terezie
    Chavez, Lia Nattero
    Lundberg, Elena
    Rica, Itxaso
    Martinez-Brocca, Maria A.
    Ruiz de Adana, Mari Sol
    Wahlberg, Jeanette
    Hanas, Ragnar
    Hernandez, Cristina
    Clemente-Leon, Maria
    Gomez-Gila, Ana
    Ferrer Lozano, Marta
    Sas, Theo
    Pruhova, Stepanka
    Dietrich, Fabricia
    Marin, Sara Puente
    Hannelius, Ulf
    Casas, Rosaura
    Ludvigsson, Johnny
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (09) : 2644 - 2651
  • [4] GAD-alum immunotherapy in type 1 diabetes expands bifunctional Th1/Th2 autoreactive CD4 T cells
    Sefina Arif
    Iria Gomez-Tourino
    Yogesh Kamra
    Irma Pujol-Autonell
    Emily Hanton
    Timothy Tree
    Daisy Melandri
    Caroline Hull
    Diane K. Wherrett
    Craig Beam
    Bart O. Roep
    Anna Lorenc
    Mark Peakman
    Diabetologia, 2020, 63 : 1186 - 1198
  • [5] GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes
    Skoglund, Camilla
    Cheramy, Mikael
    Casas, Rosaura
    Ludvigsson, Johnny
    Hampe, Christiane S.
    PEDIATRIC DIABETES, 2012, 13 (03) : 244 - 250
  • [6] GAD-alum immunotherapy in type 1 diabetes expands bifunctional Th1/Th2 autoreactive CD4 T cells
    Arif, Sefina
    Gomez-Tourino, Iria
    Kamra, Yogesh
    Pujol-Autonell, Irma
    Hanton, Emily
    Tree, Timothy
    Melandri, Daisy
    Hull, Caroline
    Wherrett, Diane K.
    Beam, Craig
    Roep, Bart O.
    Lorenc, Anna
    Peakman, Mark
    DIABETOLOGIA, 2020, 63 (06) : 1186 - 1198
  • [7] High-risk genotypes HLA-DR3-DQ2/DR3-DQ2 and DR3-DQ2/DR4-DQ8 in co-occurrence of type 1 diabetes and celiac disease
    Schweiger, Darja Smigoc
    Mendez, Andrijana
    Jamnik, Sabina Kunilo
    Bratanic, Nina
    Bratina, Natasa
    Battelino, Tadej
    Brecelj, Jernej
    Vidan-Jeras, Blanka
    AUTOIMMUNITY, 2016, 49 (04) : 240 - 247
  • [8] GAD-specific T cells are induced by GAD-alum treatment in Type-1 diabetes patients
    Pihl, Mikael
    Barcenilla, Hugo
    Axelsson, Stina
    Cheramy, Mikael
    Akerman, Linda
    Johansson, Ingela
    Ludvigsson, Johnny
    Casas, Rosaura
    CLINICAL IMMUNOLOGY, 2017, 176 : 114 - 121
  • [9] Redosing with Intralymphatic GAD-Alum in the Treatment of Type 1 Diabetes: The DIAGNODE-B Pilot Trial
    Casas, Rosaura
    Tompa, Andrea
    Akesson, Karin
    Teixeira, Pedro F.
    Lindqvist, Anton
    Ludvigsson, Johnny
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (01)
  • [10] GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response
    Cheramy, Mikael
    Skoglund, Camilla
    Johansson, Ingela
    Ludvigsson, Johnny
    Hampe, Christiane S.
    Casas, Rosaura
    CLINICAL IMMUNOLOGY, 2010, 137 (01) : 31 - 40
12345